Deng Wei, Jia Jun
Department of Stomatology, The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, Jiangxi Province, China.
Med Hypotheses. 2008;70(4):842-4. doi: 10.1016/j.mehy.2007.07.032. Epub 2007 Sep 14.
In view of the limited success of available treatment modalities for metastatic tumor, alternative and complementary strategies need to be developed. Oncolytic viruses are capable of selective replication in malignant cells and therefore offer levels of potency and specificity that are potentially far higher than conventional treatments for tumor. However, lack of systemic delivery technique for therapeutic viruses impacts their application in treating patients with multiple disseminated metastases. Recent studies have demonstrated that when being transplanted, endothelial progenitor cells can migrate via peripheral blood and home exclusively to the site of tumor neovasculature. We hypothesized that endothelial progenitor cells can act as "Trojan horse" to systemically deliver oncolytic virus to metastases in order to inhibit tumor neovascularization formation and eventually eradicate the metastatic tumor.
鉴于现有转移性肿瘤治疗方式的成效有限，需要开发替代和补充策略。溶瘤病毒能够在恶性细胞中进行选择性复制，因此其效力和特异性水平可能远高于传统肿瘤治疗方法。然而，缺乏治疗性病毒的全身递送技术影响了它们在治疗多发性播散性转移患者中的应用。最近的研究表明，内皮祖细胞移植后可通过外周血迁移并特异性归巢至肿瘤新生血管部位。我们推测，内皮祖细胞可作为“特洛伊木马”将溶瘤病毒全身递送至转移灶，以抑制肿瘤新生血管形成并最终根除转移性肿瘤。
